Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics (PRLD) reported its FY23 financial results, showing an EPS of $(2.02) compared to $(2.44) YoY. The company has a cash runway into 2026 with $232.9M in cash and equivalents. Key 2024 objectives include advancing its SMARCA2 degrader and CDK9 inhibitor, with expected proof-of-concept data. A partnership with AbCellera aims to develop precision ADCs. R&D expenses increased to $103.4M, while G&A expenses decreased to $28.9M. The net loss was $121.8M or $2.02 per share.
February 15, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prelude Therapeutics reported improved FY23 financial results with a narrower EPS loss and a strong cash position, alongside promising developments in its oncology pipeline and a strategic partnership with AbCellera.
The improvement in EPS and the strong cash position indicate financial stability and the potential for sustained R&D investment. The strategic partnership with AbCellera and progress in the oncology pipeline, particularly with the SMARCA2 degrader and CDK9 inhibitor, suggest potential for significant future growth and positive impact on stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100